Chen W Q, Zuo T T, Zheng R S, Zeng H M, Zhang S W, He J
National Office for Cancer Prevention and Control, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Department of Thoracic Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Zhonghua Zhong Liu Za Zhi. 2017 Oct 23;39(10):795-800. doi: 10.3760/cma.j.issn.0253-3766.2017.10.015.
Lung cancer incidence and mortality were estimated by sorting and analyzing the national cancer registration data in 2013. Lung cancer data of 2013 were retrieved from the database of 255 qualified cancer registries. Lung cancer incidence and mortality rates in cancer registration areas in 2013 were estimated by areas (urban/rural), gender and age groups, new lung cancer cases and deaths were estimated using age-specific rates by areas and gender using the corresponding population in 2013. Lung cancer incidence and mortality rates in China in 2013 were calculated based on the estimated new cancer cases and deaths and the corresponding population. The Chinese population in 2000 and Segi's world population were used to calculate age-standardized rates. It was estimated that there were about 732.8 thousand new lung cancer cases and 580.7 thousand deaths occurred in China in 2013. The crude incidence rate was 53.86/10(5)(males 70.10/10(5,) females 36.78/10(5)), while age-standardized incidence rate by Chinese standard populations (ASIRC) and by world standard populations (ASIRW) were 36.19/10(5) and 36.09/10(5) with the cumulative incidence rate (0-74 years old) of 4.42%.The crude mortality rate was 43.41/10(5)(males 57.64/10(5,) females 28.45/10(5)), and age-standardized mortality rate by Chinese standard populations (ASMRC) and by world standard populations (ASMRW) were 28.64/10(5) and 28.41/10(5) with the cumulative incidence rate (0-74 years old) of 3.34%.Both incidence and mortality rates were higher in males than in females. Crude incidence and mortality rates were slightly higher in urban areas than in rural areas, but after age standardized, the results were opposite. Lung cancer is the common cancer, which both incidence and mortality rates are ranking first in China, and the burden of the disease is heavy. Comprehensive measures towards risk factors control, cancer early diagnosis and treatment should be strengthened continuously.
通过整理和分析2013年全国癌症登记数据来估算肺癌发病率和死亡率。2013年肺癌数据从255个合格癌症登记处的数据库中获取。根据地区（城市/农村）、性别和年龄组估算2013年癌症登记地区的肺癌发病率和死亡率，采用2013年相应地区和性别的特定年龄发病率及相应人口来估算新的肺癌病例数和死亡数。基于估算的新癌症病例数和死亡数以及相应人口计算2013年中国的肺癌发病率和死亡率。使用2000年中国人口和世标人口计算年龄标准化率。据估计，2013年中国约有73.28万例新发肺癌病例，58.07万例死亡。粗发病率为53.86/10万（男性70.10/10万，女性36.78/10万），中国标准人群年龄标准化发病率（ASIRC）和世界标准人群年龄标准化发病率（ASIRW）分别为36.19/10万和36.09/10万，累积发病率（0至74岁）为4.42%。粗死亡率为43.41/10万（男性57.64/10万，女性28.45/10万），中国标准人群年龄标准化死亡率（ASMRC）和世界标准人群年龄标准化死亡率（ASMRW）分别为28.64/10万和28.41/10万，累积发病率（0至74岁）为3.34%。发病率和死亡率均男性高于女性。城市地区粗发病率和死亡率略高于农村地区，但年龄标准化后结果相反。肺癌是常见癌症，其发病率和死亡率在中国均位居首位，疾病负担沉重。应持续加强针对危险因素控制、癌症早期诊断和治疗的综合措施。
